Shalini Sharp

Ms. Sharp is Executive Vice President and Chief Financial Officer of Ultragenyx, a public biopharmaceutical company focused on rare diseases, where she joined in May 2012. She led the company’s IPO and other private and public financings and is responsible for leading the finance, strategy, and information technology functions. Ms. Sharp brings to Ultragenyx over twenty years of experience in the life sciences industry.

Ms. Sharp is a member of the Board of Directors of Agenus Inc. (formerly Antigenics Inc.), a public immuno-oncology firm, where she previously served as Chief Financial Officer. She is also a member of the Board of Directors of Array Biopharma Inc., a public  small-molecule oncology company, and of the TB Alliance, a non-profit developing and distributing treatments for tuberculosis in the developing world. Prior to Agenus, Ms. Sharp held corporate finance and strategic roles at Elan Pharmaceuticals, including serving as chief of staff to the Chairman of the Board of Directors during that company's restructuring. Ms. Sharp was also a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in life sciences.

Ms. Sharp holds both a B.A. and M.B.A., from Harvard University.